iiinova — where your digital self keeps evolving

Reposted by @rautoupe.bsky.social

Wilco Kwanten @kvvanten.bsky.social · 13/05/2025

In the (early) pathophysiology of MASLD the LSEC and microvascular alterations are key. Lanifibranor improves LSEC capillarisation and dysfunction! tinyurl.com/x37637j4 #AntwerpHepatology #AntwerpHypothesis @rautoupe.bsky.social @svenfrancque.bsky.social

043

Reposted by @rautoupe.bsky.social

DECISION Horizon2020 @decision4liver.bsky.social · 10/05/2025

Is the etiological work-up of #PSVD a one-size-fits-all? DECISION consortium member Lucile Moga from APHP takes part in EASL/ VALDIG's session on "Do's and Don'ts in the management of Porto-Sinusoidal Vascular Disease". #EASLCongress #EASL2025 #LiverResearch @easlnews.bsky.social

071

Reposted by @rautoupe.bsky.social

mattiasmandorfer.bsky.social @mattiasmandorfer.bsky.social · 10/05/2025

📢 First @easlnews.bsky.social CPG on surgery in cirrhosis presented today together with the one on TIPS! 🤝 See you at 10:30 Erlinger Room! @bavenocoop.bsky.social #LiverSky

054

Reposted by @rautoupe.bsky.social

DECISION Horizon2020 @decision4liver.bsky.social · 10/05/2025

Estefania Huergo presents methylation data in AD patients, selected as best Young Investigator abstract in Basic Science at #EASL2025 - Congrats! 🎉 @navarrabiomed.bsky.social @easlnews.bsky.social #Epigenetics #LiverResearch

093

Reposted by @rautoupe.bsky.social

DECISION Horizon2020 @decision4liver.bsky.social · 10/05/2025

Back in the Abstract Session: Theresa Wirtz presents her scRNA-seq work on monocyte subsets and ACLF risk. @rwth.bsky.social @brunslab.bsky.social @easlnews.bsky.social #Cirrhosis #ACLF #EASL2025"

095

Reposted by @rautoupe.bsky.social

DECISION Horizon2020 @decision4liver.bsky.social · 10/05/2025

❤️ Cardiac performance is impaired in patients with proven alcohol-related hepatitis and predicts 3-month mortality in this patient population #POSTER SAT-503-YI by Pierre-Emmanuel Rautou (@inserm.fr, APHP, EF CLIF) 📅 Presented at the #EASLCongress | #EASL2025 @easlnews.bsky.social

094

Reposted by @rautoupe.bsky.social

DECISION Horizon2020 @decision4liver.bsky.social · 09/05/2025

How do you build&lead a successful research team? The next generation of PIs learned straight from the best in today's workshop “How to Start a Research Group: From Postdoc to PI" as @rautoupe.bsky.social shared practical insights on building&maintaining a high-performing team. @inserm.fr #EASL2025

083

Reposted by @rautoupe.bsky.social

DECISION Horizon2020 @decision4liver.bsky.social · 09/05/2025

Greetings from the DECISION Investigator Meeting at #EASL2025: Study updates and collaborative discussions with Paolo Caraceni & @rautoupe.bsky.social #ClinicalTrials #cirrhosis

052

Reposted by @rautoupe.bsky.social

DECISION Horizon2020 @decision4liver.bsky.social · 09/05/2025

Good morning! DECISION coordinator Pierre-Emmanuel Rautou just started the early morning abstract session on #cirrhosis at the #EASLCongress in Amsterdam. You can still join in the Benhamou Room until 09.45am! @easlnews.bsky.social

073

Reposted by @rautoupe.bsky.social

DECISION Horizon2020 @decision4liver.bsky.social · 09/05/2025

Next at the DECISION Networking Session at #EASL2025, Theresa Wirtz (UKA) presents scRNA-seq data showing a monocyte subset linked to ACLF risk. Fascinating translational science in action! @brunslab.bsky.social ky.social @easlnews.bsky.social ky.social #scRNAseq #ACLF

0117

Reposted by @rautoupe.bsky.social

DECISION Horizon2020 @decision4liver.bsky.social · 09/05/2025

Lastly at DECISION's Networking Session, Richard Moreau shares new data: high-throughput omics reveals biomarkers for infection & poor outcomes in cirrhosis. @inserm.fr @easlnews.bsky.social sky.social #Metabolomics #Cytokinomics #EASL2025

073

Reposted by @rautoupe.bsky.social

rautoupe.bsky.social @rautoupe.bsky.social · 15/03/2025

📢📢 looking for a co-founder (CEO) for an early stage medtech startup‼️ Our goal: bring extracellular vesicles from the lab to the bedside of patients with chronic liver disease.🧪 Find the offer here: www.lesdeeptech.fr/tandem/41693...

021

Reposted by @rautoupe.bsky.social

DECISION Horizon2020 @decision4liver.bsky.social · 09/05/2025

Kicking off our #EASL2025 Networking Session with an intro to the DECISION project by coordinator Pierre-Emmanuel Rautou - Let’s talk systems medicine, cirrhosis, and precision care! @rautoupe.bsky.social pe.bsky.social @easlnews.bsky.social ky.social #LiverDisease

094

rautoupe.bsky.social @rautoupe.bsky.social · 21/03/2025

Interested in vascular liver diseases and more broadly in liver and vessels? ▶️Join the COST Action EURO-VALDI-NET: www.cost.eu/actions/CA23... Eligibility criteria there: www.cost.eu/am-i-eligible/

cost.eu

European vascular liver diseases network

Vascular liver diseases are a heterogeneous group of rare disorders characterized by an impaired vascular flow in the splanchnic and/or intrahepatic vasculature. They mainly include recent portal...

011

rautoupe.bsky.social @rautoupe.bsky.social · 15/03/2025

021

rautoupe.bsky.social @rautoupe.bsky.social · 22/02/2025

📢📢 Analysis of 249 patients with MASLD and of 2 rat models: ⚠️Liver endothelial cell (LSEC) capillarisation appears before MASH onset ❌LSEC capillarisation progresses with liver fibrosis and inflammation ✅Lanifibranor improves LSEC function authors.elsevier.com/sd/article/S...

000

rautoupe.bsky.social @rautoupe.bsky.social · 18/02/2025

Tips for managing invasive procedures in patients with cirrhosis 🩸🩸: ➡️What limits of laboratory values❓ ➡️How to risk stratify procedures❓ ➡️When to stop and restart anticoagulants and antiplatelet agents❓ Find this and more there: doi.org/10.3350/cmh....

000

rautoupe.bsky.social @rautoupe.bsky.social · 08/02/2025

📢📢Interested in vascular liver diseases❓ Check the opportunities for: ✅Short Term Scientific Mission 🧳 Deadline Feb 21 ✅Conference Grants Deadline March 14 ➡️ more details there www.valdig.eu/cost-action-...

010

Reposted by @rautoupe.bsky.social

Rui Castro @ruicastrohd.bsky.social · 24/01/2025

@rautoupe.bsky.social provides an update on endothelium-platelet interactions in SLD: 🎯 LSEC capillarisation increases with liver fibrosis in MASLD 🎯 Aspirin improves MASLD 🎯 Likely by inhibiting platelet accumulation and/or platelet EV release @easlnews.bsky.social #SLDSummit

041

Reposted by @rautoupe.bsky.social

LIVER-TRACK @livertrack.bsky.social · 20/01/2025

➡️ Following by Marion Biquard's speech on the measurement of the EV proteins 🧬 @rautoupe.bsky.social @ap-hp.bsky.social @institutcurie.bsky.social

121

Reposted by @rautoupe.bsky.social

LIVER-TRACK @livertrack.bsky.social · 20/01/2025

🔬The proteomic aspect of the LIVER-TRACK project was presented by Prof. Laure Elkrief 🩺 @rautoupe.bsky.social @cri1149.bsky.social

111

Reposted by @rautoupe.bsky.social

LIVER-TRACK @livertrack.bsky.social · 20/01/2025

🧪The Curie Core Tech team is an essential partner for the proteomics aspect of the RHU LIVER-TRACK project. We are very pleased with their contribution alongside us🙏 @institutcurie.bsky.social @ap-hp.bsky.social @rautoupe.bsky.social

111

Reposted by @rautoupe.bsky.social

LIVER-TRACK @livertrack.bsky.social · 20/01/2025

➡️Catlado Schietroma from Abbelight, a partner in the RHU LIVER-TRACK project,has presented the progress of their work in WP3 of LIVER-TRACK🧬🧬 @rautoupe.bsky.social

111

Reposted by @rautoupe.bsky.social

LIVER-TRACK @livertrack.bsky.social · 20/01/2025

🙏A big thank you to Prof. Cedric Laouenan🩺 for his insightful presentation during the Livertrack General Assembly! Your contribution was highly appreciated👌 #Livertrack #GeneralAssembly #Gratitude @hopitalbichat.bsky.social @rautoupe.bsky.social @ap-hp.bsky.social

121

Reposted by @rautoupe.bsky.social

LIVER-TRACK @livertrack.bsky.social · 20/01/2025

▶️ A real pleasure to hear Professor Durand Zaleski discuss the medical-economic costs and what will be done in the RHU LIVER-TRACK project 💸💸 Looking forward to the upcoming developments! #LiverTrack #MedicalEconomics #RHU @ap-hp.bsky.social @rautoupe.bsky.social @hoteldieuparis.bsky.social

111

Reposted by @rautoupe.bsky.social

LIVER-TRACK @livertrack.bsky.social · 20/01/2025

🔝What a pleasure to welcome Professor Annalisa Berzigotti from the University of Bern🇨🇭 for a keynote lecture following our General Assembly. Thank you so much 👏 #Rhu #Livertrack #SABmeeting @rautoupe.bsky.social @ap-hp.bsky.social

011

Reposted by @rautoupe.bsky.social

LIVER-TRACK @livertrack.bsky.social · 20/01/2025

🩺 Professor Rautou, the project coordinator, welcomed the partners to the meeting by giving an overview of the LIVER-TRACK project ▶️ @rautoupe.bsky.social @ap-hp.bsky.social @upcite.bsky.social

021

Reposted by @rautoupe.bsky.social

LIVER-TRACK @livertrack.bsky.social · 20/01/2025

🔙 A look back to the fantastic General Assembly of LIVER-TRACK! 🙌 A big thank you to all our partners for being there and to our experts for their valuable insights and availability. Your contributions made it a success! 💡🤝 #LiverTrack #GeneralAssembly @rautoupe.bsky.social @ap-hp.bsky.social

011

Reposted by @rautoupe.bsky.social

LIVER-TRACK @livertrack.bsky.social · 12/01/2025

🚨 T-5 Days until our General Assembly & SAB! 🚨 We can’t wait to see you all and share the latest progress of our project. Exciting times ahead as we welcome our experts to join us and contribute to the discussion! 🔥 Stay tuned for more updates! #LiverTrack @rautoupe.bsky.social @ap-hp.bsky.social

011

Reposted by @rautoupe.bsky.social

LIVER-TRACK @livertrack.bsky.social · 02/01/2025

🎉 The Livertrack team wishes you a very Happy New Year 2025! 🥳 May this year be filled with success, joy, and new opportunities. Here's to a fantastic year ahead! 🚀 #HappyNewYear #2025 #Livertrack @rautoupe.bsky.social @inserm.bsky.social @institutcurie.bsky.social @ap-hp.bsky.social

021

Reposted by @rautoupe.bsky.social

Annalisa Berzigotti @docberza.bsky.social · 10/12/2024

The second EASL Lancet commission coordinated by Tom Karlsen met in Geneva - we need to improve liver health in Europe and we worked to better understand how it can be done. Inspiring experience and great work in progress @thelancet.bsky.social @ec.europa.eu @aleksanderkrag.bsky.social

161

rautoupe.bsky.social @rautoupe.bsky.social · 26/12/2024

Hepato-pulmonary syndrome (HPS) in 196 patients with PSVD: ▶️prevalence: 7% ▶️risk factors: telomere biology disorders & less preserved liver function ▶️outcome similar to PSVD patients w/o HPS when applying HPS MELD exception policy for transplantation jhep-reports.eu/article/S258...

030